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There is compelling support for limiting expression of alpha-synuclein (α-syn) in the brains of Parkinson’s disease (PD) patients.
AnincreaseofSNCAgenecopynumbercangeneticallycausefamilialPDwhereincreaseddoseofthispathogenicproteincorrelates
with severity of symptoms (triplication of the SNCA gene causes dementia in PD patients). Gene promoter polymorphisms
were shown to increase α-synuclein expression as a risk for PD. Cholinesterase inhibitors can clinically slow cognitive decline
in the later stages of PD etiology similar to their widespread use in Alzheimer’s disease (AD). Pertinent to this, we identiﬁed
that the well-tolerated anticholinesterase, phenserine, blocked neural SNCA mRNA translation and tested for targeting via its
5 untranslated region (5 UTR) in a manner similar to its action to limit the expression of the AD-speciﬁc amyloid precursor
protein (APP). Posiphen, its better-tolerated (+) enantiomer (devoid of anticholinesterase action), repressed neural α-synuclein
translation. Primary metabolic analogs of posiphen were, likewise, characterized using primary fetal neurons grown ex vivo from
the brains of Parkinson’s transgenic mice expressing the human SNCA gene.
1.Introduction
Parkinson disease (PD) is a slowly progressive neurodegen-
erative disease aﬀecting up to 3% of the population over the
age of 65 years. Clinically, it is characterized by a set of
motor symptoms and nonmotor symptoms that can include
dementia. Motor symptoms include rigidity, postural insta-
bility, bradykinesia, and resting tremor [1, 2]. The core
pathological feature correlating with most of these motor
symptoms is a loss of dopaminergic neurons from the sub-
stantia nigra pars compacta (SNc). Pathological inclusions,
known as Lewy bodies, are found within some of the
remaining dopaminergic neurons [3]. The destruction of the
dopaminergic neurons atonsetis atleast70%and, attheend
stage of the disease the loss of dopamine (DA) neurons, can
exceed 95% [3]. Therapy for the symptoms of PD is based
primarily on replacement of dopaminergic function and can
be remarkably eﬀective in alleviating motor symptoms for
an u m b e ro fy e a r s[ 1, 4]. Additional nonmotor symptoms
can be present and include depression, anxiety, sensory
abnormalities, anosmia, sleep, and autonomic disorders, in
addition to dementia [1, 5–8].
Particular nonmotor symptoms, like sleep disturbances
[9], loss of smell [6, 10], and depression, can occur well
before the presence of detectable motor symptoms [5]. The
presence of psychotic symptoms, which can aﬀect up to 40%
of the patients, is often associated with anti-parkinsonian2 Parkinson’s Disease
treatment and is dose dependent [2, 7]. By contrast, the neu-
ropsychiatricsymptomsofPD,likedepressionanddementia,
are more common at the later stages of the disease [6, 8,
11, 12]. These neuropsychiatric symptoms may be correlated
directly to the progression of PD itself as in PD dementia or
PDD, to the presence of Dementia with Lewy Bodies (DLB)
or to the presence of comorbidities like Alzheimer’s Disease
(PD/AD) [2]. The incidence of dementia in PD is six times
higherthaninage-matchedcontrols;inallformsofdementia
associated with PD, the use of cholinesterase inhibitors may
be beneﬁcial [2, 13–17].
T h ee t i o l o g yo fP Di ss t i l le l u s i v e[ 18]. A variety of
genetic factors have been linked to the etiology of familial
PD[19].Theﬁrstwastheproteinalpha-synuclein(α-syn),an
abundant brain protein that appears to be involved in vesicle
traﬃcking and participates in the regulation of DA release
[20]. The ﬁrst reports to implicate α-syn in PD described
mutations in the protein, which cause autosomal dominant
forms of the disease [21, 22]. Subsequent studies revealed
that such mutations were exceedingly rare but also that
aggregates of α-syn could be found in all cases of familial
and sporadic PD [23]. It is important to recognize that the
genetic mechanisms identiﬁed to date are individually rare
and, collectively, represent only a small fraction of the cases
of PD observed by practitioners. This hence leaves the vast
majority of PD unexplained at present.
Events associated with the inﬂammatory cascade [24]a s
well as with iron metabolism [25, 26] and translational con-
trol of gene expression have been modeled to be associated
with PD and LBD [27]. There are also reported examples
of disrupted signaling events such as occuring in response
to inﬂammation cytokines: for example, mutations to the
signaling kinase LRRK-2 may activate inﬂammatory events
in this neurodegenerative disease [24, 28], perhaps aﬀecting
novel signalling pathways [24]. Certainly, increased iron in
the individual dopaminergic neurons of the substantia nigra
(SN) has been reported to be closely associated with the
pathogenesis of PD [29], and antioxidants have been tested
as a means to alleviate the severity of PD [30]. DLB brains
exhibit lowered SNCA mRNA but higher insoluble protein,
suggesting misregulation of SNCA mRNA translation addi-
tional to its clearance by chaperones [31], although reduced
autophagy may provide the explanation. Translational con-
trol of α-syn may be governed, at least in part, by a uniquely
conﬁgured 5 untranslated region (5 UTR) of its transcript,
which encodes a homology with the known APP and ferritin
iron-responsive elements [32–35].
α-Synuclein is, in fact, the central ∼15kDa protein
implicatedinthepathogenesisofneurodegenerative α-synu-
cleinopathies [36], including PD—the most prevalent move-
ment disorder in humans. Other alpha synucleinopathies
include DLB, Lewy body variant of Alzheimer’s disease
(AD), and multiple system atrophy. In these disorders, α-
synundergoesaconformationalchangeandoligomerization,
causing a toxic gain of function. Neurodegenerative dep-
osition of α-syn aggregates occurs, most commonly in Lewy
bodies. Lewy bodies are rare in PD patients, present only
in the surviving neurons. α-syn aggregates are in dys-
trophic neurites. Glial cytoplasmic inclusions are in multiple
systems atrophy [37]. Pathogenic pathways of α-synuclein
and amyloid-β (Aß) converge via interaction of these two
amyloidogenic proteins, which coprecipitate into ß-pleated
oligomers and insoluble ﬁbrils [38–40], although Aß and α-
syn rarely colocalize in brain amyloid deposits [41]. There
is certainly also overlap between the 5 UTRs of the SNCA
and amyloid precursor protein (APP) transcripts, another
similarity that provides a further link between PD and AD
[27, 33–35].
Such overlap in the 5 UTRs of SNCA and APP mRNAs is
consistent with our and other groups’ recent demonstrations
that both are key players in iron metabolism and α-syn
may be translationally controlled by cellular iron levels as
was demonstrated for APP expression [35, 42]. In this
regard, APP is a copper-dependent iron export ferroxidase
[43], and α-syn a Cu-binding ferrireductase [44, 45]. These
similarities, together with the utility of anticholinesterases in
AD and PD, provided our rationale to test whether known
anticholinesterases that are beneﬁcial and Aβ lowering [46]
would, likewise, provide anti-α-syn activity in neural cells.
The most common therapy for PD is L-dopa that is
routinely used to overcome the archetypical problems of
tremor. As disease progresses, however, clinically available
anticholinesterases have been increasingly empirically used,
based in part on an putative impairment of the cholinergic
system in developing PD [47].
Therefore, our study investigated the eﬀectiveness of the
cholinesterase inhibitor phenserine and its noncholinergic
(+) chiral enantiomer, posiphen in lowering α-synuclein
expression in neural cell lines. Both agents have been shown
to eﬀectively lower APP synthesis rate both in neuronal
cultures and animals via translational regulation mediated
at the level of the APP mRNA 5 UTR. As both agents have
been developed through to clinical studies and appear well
tolerated in AD, if eﬀective in reducing α-syn levels, they
hold translational promise as potential therapeutics for PD.
Furthermore, as posiphen can be eﬀectively dosed in
rodents and humans in far greater amounts than phenserine,
thereby generating high levels of its primary metabolites,
the three most prominent primary metabolic products of
posiphen were also characterized. As a model to examine
the α-syn-lowering eﬃcacy of these agents, we assessed
the cellular therapeutic impact of these screened SNCA
5 UTR-directed translation blockers to reduce α-synuclein
expression in neural cells lines and subsequently also in the
primary neurons from the PAC/Tg(SNCA)g e n o m i ch u m a n
SNCA mouse model of PD (Figures 2 and 6)[ 48].
1.1. Hypothesis/Model. Our model to be tested is shown in
Figure 7. The overarching hypothesis is that the drug phen-
serine (anticholinesterase) and its enantiomer are known
translation blockers of the amyloid precursor protein of
Alzheimer’s disease (AD) and, as such, have been tested in
clinical trials for their antiamyloid eﬃcacy and potential
to improve cognition. We noted that the RNA target in
the 5 UTR of APP mRNA was similar to that found in
the alpha-synuclein transcript. Therefore, we decided to
see if posiphen and phenserine might block α-synuclein,Parkinson’s Disease 3
the central culprit protein in PD. To achieve this end, we
conducted Western Blot experiments ﬁrstly with SH-SY5Y
dopaminergic neuroblastoma cells and then with primary
E18 neurons from a genomic mouse model of PD. Our ratio-
nale for conducting this study was to determine if posiphen
and phenserine are two 5 UTR-directed drugs that would
reduce alpha-synuclein expression to provide therapeutic
beneﬁt to Parkinson’s disease patients.
2.MaterialsandMethods
2.1. Materials. Dulbecco’s modiﬁed essential medium
(DMEM, catalog no. 12-614Q); FBS (catalog no. 14-503E),
L-glutamine (catalog no. 17-605E), penicillin/streptomycin
(catalog no. 17-602E); phenol red free media (phenol red-
free DMEM with 4.5g/L D-glucose (catalog no. 12-
917F)) were purchased from Lonza (Portsmouth, NH).
Trypsin/EDTA (catalog no. 25-053-Cl) was purchased from
Cellgro. Steady-Glo (catalog no. E2250) was purchased from
Promega (Madison, WI). For the Western Blot secondary
screen, penicillin/streptomycin was acquired from Bio-
Whittaker (Walkersville, MD), mouse monoclonal anti-
alpha-synuclein waspurchased fromBDTransduction Labo-
ratories, and anti-beta-actin was acquired from Chemicon,
Inc. We routinely use 384-well plates (catalog no. 3570),
which were purchased from Corning and Falcon TC ﬂasks
(catalog no. 353112) were purchased from Becton Dickinson
(Waltham, MA). SH-SY5Y cells were purchased from the
ATCC, Manassas, VA.
2.2. Cell Culture. Transfected SH-SY5Y neuroblastoma cells
were grown to conﬂuency in 35mL complete DMEM with
4.5g/L D-glucose supplemented with 10% FBS, 200μML -
glutamine, 100μM penicillin/streptomycin, and 200μg/mL
geneticin in a T175 TC ﬂask in a TC incubator (37◦C,
95% humidity, 5% CO2) (doubling time = 24h). Untrans-
fected SH-SY5Y counterparts were grown in the absence of
geneticin. Cells were harvested by washing the monolayer
quickly with 5mL trypsin/EDTA (1X), aspirating, then
adding5mLtrypsin/EDTAandincubatingfor5minat37◦C,
95% humidity, 5% CO2, after which cells were collected into
phosphate-buﬀered saline and centrifuged into a pellet for
storage at −70◦C.
Primary cortical neurons from wild-type mice and from
the PAC-Tg(SNCA(wt) human SNCA genomic mice [48]
were cultured as outlined by the method of Ray et al.,
2009 [49]. Brieﬂy, we recovered the embryonic day 15–
18 pups after sacriﬁcing pregnant females, separated out
the brain, and removed the meninges and blood vessels.
We then dissected out the cortices and placed them in
separateeppendorftubescontaining500uLofHBSSwithout
Ca+2/Mg+2 salts supplemented with 1mM sodium pyruvate
and 10mM HEPES, pH 7.4. On ice, individual cells were
isolated by titurating 10 times using a glass pasture pipette
with the tip barely ﬁre polished. We adjusted the volume to
1.5mL, by adding 1mL of HBSS with Ca+2/Mg+2 salts + Na
pyruvate + HEPES, restoring the divalent cations by adding
HBSS so that the nondispersed tissue could settle for 5min,
on ice. In the tissue culture laminar hood, we transferred the
supernatant into a new 15mL tube and centrifugedfor 1min
at 900rpm, 4◦C. We gently resuspended the pellet in 2mL
of HBSS with Ca+2/Mg+2 salts + Na pyruvate + HEPES and
took an aliquot for counting (2mL for approx. 5 embryos).
We then plated ∼ 1 × 105 cells/well of a 24-well or 2 ×
105/in 12-well plates. Each set of plates were coated with
poly D-lysine containing poly L-lysine coverslips for micro
immunocytochemical conﬁrmation of neuronal integrity.
2.3. Bioinformatics Methods. The α-synuclein RNA sequen-
ces were selected using the NCBI Gene search and the En-
sembl database (see [34]). Since the 5  UTRs were of
primary interest, the coding sequences (CDS) were mostly
disregarded, apart from the initiating AUG. As we reported
[34], the splice junction between two exons occurred at a
CAGUGU site 25 = nucleotides from the AUG and that this
pattern was conserved among the other species investigated.
Thus, in order to study a balanced sequence, 25 nucleotides
before the splice junction from the ﬁrst exon were used to
create 50 nucleotide RNA sequences (mouse and rat had 52
nt sequences due to insertions).
The ClustalX2 graphical program was used to align the
RNA sequences to identify any evolutionary conservation
between species. For alpha synuclein, the AUG start region
of the CDS was a reference point for sequence alignments,
allowingacomparisonofthesequencesinbothexonsaround
the splice junction, due to high local conservation ﬁdelity.
Secondary sequences were then generated by the University
of Vienna’s RNAfold webserver (with standard settings) and
were annotated using the RNAfold command-line software.
The RNAfold server provided the most probable secondary
structure based on minimum-free energy calculations.
We calculated the alignment homology by comparing
any species’ RNA sequence (as listed) against the Homo
sapiens sequence on each side of the splice junction. We also
calculated the homology between the core L- and H-ferritin
IREs with that of alpha synuclein and APP mRNAs. Only
nucleotides that matched respective to the Homo sapiens
sequence were scored a point; we determined the percent
homology on each side by totaling the points scored and
dividing by the total number of nucleotides on that side. The
results from each side were then compared to illuminate the
diﬀerence in conservation across the splice junction.
2.4. Constructs. The SNCA-5 UTR-pGL3 construct was gen-
erated from the pGL3 expression vector (Promega). In this
case, a PCR fragment encoding 48 base α-synuclein 5 UTR
was cloned between the Hind-III and Nco1 sites in front
of start codon of the luciferase gene in PGL3. Transiently
transfected cells expressed either pGL3 or the SNCA-5 UTR-
pGL3 construct. Stably transfected neural cell lines were
generated via neomycin selection after cotransfection with
the RSV2-neomycin plasmid to express the SNCA-5 UTR-
pGL3 construct (H2A cells) or pGL3 (control cells).
2.5. Stable-Transfection-Based Screen of a Library of Natural
Product Inhibitors of α-Synuclein Translation. A 720 com-
pound natural products, including added phenserine and4 Parkinson’s Disease
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our identiﬁcation of cotranslational repression of APP and alpha-synuclein by small molecules, such as phenserine and posiphen.
posiphen, from Microsource Discovery Systems, Inc, was
screened at a concentration of 2uM in triplicate for inhi-
bition of luciferase expression using (APP cells) and (SNCA
cells). A compound was scored as a hit if all replicates gave
>65% inhibition in this assay, and as contradictory if at least
one, but not all replicates gave >65% inhibition. In order
to rule out compounds that reduced luciferase expression
due to toxicity, the entire library was also screened in both
cell lines for cytotoxicity, using alamar blue (Biosource, Inc.)
as the readout. Percent inhibition in the alamar Blue assay
was calculated and compared with percent inhibition of
luciferase activity. Posiphen and phenserine were among the
compounds for which the diﬀerence was greater than 40 and
which scored as a hit or contradictory in the luciferase assay.
2.6. Transient Transfection Assays. After 24hr transfection
of SH-SY5Y cells in a 100mm dish with either (i) SNCA-
5 UTR-pGL3 or (ii) pGL3 parental vector, cells were then
passaged into 6 wells and tested with posiphen and phenser-
ine (15μM = for 48hr) as shown in Figures 3 and 4 for
whichdose-responseassayswerealsoconducted(notshown)
[34, 50].
2.7. Luciferase Assay. Cells were plated at 2000 cells/well
(APP) or 4000 cells/well (SNCA) in a 384-well white ﬂat-
bottom plate (Greiner) in a volume of 50uL of media. Fol-
lowing overnight incubation, 50nL of 5μMi nD M S Ow e r e
added using a VPN Pintool. Cells were returned to the
incubator of 48h, then assayed for luciferase activity. Plates
were allowed to equilibrate to room temperature. After
addition of 25uL Steady-Glo reagent (Promega), plates were
vortexed for 30sec and 35 minutes later luminescence read
on an Inﬁnite F2000 plate reader (Tecan) [34, 50].
2.8. Western Blot Assay. Human SH-SY5Y cells and primary
cortical neurons (E18 fetal cells) were exposed to increasing
concentrations of phenserine and posiphen for 48 hours.
Cytoplasmic protein lysates were prepared by homogenizing
the cells in midRIPA buﬀer (25mM Tris pH 7.4, 1%
NP40, 0.5% sodium deoxycholate, 15mM NaCl, protease
inhibitors, RNase inhibitor, and 10μM DTT). Western Blot-
ting for alpha-synuclein was performed using mouse mono-
clonal anti-alpha-synuclein (BD Transduction Laboratories)
and anti-beta-actin (Chemicon). The blots were developed
using chemiluminescence (PIERCE) and visualized with a
PhosphoImager (BioRad, Hercules, CA), and bands were
quantiﬁed using QuantityOne software (BioRad).
3. Results and Discussion
In Figure 1, we performed a full bioinformatic analysis
of the SNCA 5 UTR demonstrating by computer-mediated
predictions [50] that the 5 UTR of the SNCA transcript folds
into a unique RNA stem loop resembling an iron-responsive
element (IRE) RNA structure that is related to, but distinct
from, the H-ferritin and APP 5 UTR-speciﬁc IREs [33].
We are currently testing the capacity of intracellular iron
chelationwithdesferrioxaminetorepressneural α-synuclein
translation acting via the IRE in the 5 UTR of its transcript,
as we reported for the APP and ferritin mRNAs [42, 51].
Previously, the RNA-directed anticholinesterase drug
phenserine, together with its cholinergically inert chiral (+)6 Parkinson’s Disease
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Figure 2: Posiphen and phenserine decrease both APP and α-synuclein levels dose-dependently in dopaminergic SH-SY5Y cells. Panel A:
the 5 UTRs of both the APP and SNCA genes are 50% homologous with the IRE H-ferritin mRNA. Panel B: SH-SY5Y cells were treated
with concentrations ranging from 0 to 10μM phenserine and posiphen for 48h. Harvested cell lysates were prepared. Quantitative Western
Blotting established the anti-α-syn eﬃcacy of posiphen and phenserine (IC50 < 5μM); after standardization for β-actin (Densitometry
of multiple lanes (n = 8) by ImageQuant). Cell viability was unaﬀected (measured by standardized ATP levels/cell (Tm (Cell-Titer-glo,
Promega, Inc.))).
enantiomer, posiphen, which are both in clinical devel-
opment for AD, was shown to therapeutically limit brain
Aβ levels in wild-type and AD mouse models [46]. This
action was mediated, in whole or in part, by lowering the
rate of synthesis of APP, from which Aβ is proteolytically
cleaved. Here, we sought to demonstrate that phenserine
and posiphen, likewise, blocked α-synuclein expression via
their related 5 UTRs, encoding variant versions of the iron-
responsive element RNA elements that potentially bind iron-
regulatory proteins.
To elucidate whether our deﬁned target would translate
across species, we provide the results of an evolutionary eval-
uation of the conservation of IRE RNA stem loops in SNCA
mRNA as shown in Figure 1. This is the RNA secondary
structure sequence, together with the APP 5 UTR, that is
targeted by phenserine and posiphen, as shown in Figures
2–4. The alpha-synuclein-speciﬁc IRE stem loop was formed
at the splice junction of the ﬁrst two exons in SNCA
gene [35]. We also compared the predicted structure of
the SNCA mRNA IRE with the canonical IREs in the H-
ferritin and APP transcripts, which are transcribed from the
single ﬁrst exon of their genes conﬁrming the uniqueness of
translational repression of SNCA mRNA via its 5 UTR.
The anticholinesterase phenserine and its (+) enanti-
omer, posiphen, are proven APP 5 UTR mediated drugs
with known pharmacokinetics in rodents and humans and
identiﬁedtargetconcentrations[46,52].Sinceweanticipated
that both agents would be active in limiting α-synuclein
translation via its 5 UTR, we had spiked an FDA library with
posiphen and phenserine when we formerly screened against
the SNCA 5 UTR RNA target [34]. Here, we conﬁrm that
both posiphen and phenserine repressed the SNCA 5 UTR-
driven translation of a luciferase reporter in stable cells lines.
Their capacity to inhibit SNCA mRNA translation is similarParkinson’s Disease 7
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Figure 3: Posiphen is a stereospeciﬁc inhibitor of alpha synuclein 5 UTR-directed translation. Transient transfection assays with the SNCA-
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to that of certain other deﬁned FDA drug leads, including
three glycosides and an immunosuppressant, mycophenolic
acid (secondary Fe chelator), as we previously reported [34].
In Figure 2(a), the 5 UTRs of both APP and SNCA
showed 40% homology to each other and also 50% homol-
ogy to the IRE in H-ferritin mRNA. Multiple Western blot
experiments were hence conducted to determine the impact
of phenserine compared to posiphen to limit α-syn com-
pared to APP expression. In this regard, SH-SY5Y cells
were treated with both compounds for 48 hours with
concentrations ranging from 0 to 10μM. Viability studies
determined that this range was well tolerated, in accordance
with prior studies. In general and as shown in Figure 2(b),
posiphen (in addition to but potentially slightly more
potently than phenserine) decreased levels of α-s y ni na
dose-dependent manner in cultured neural cells (SH-SY5Y)
as previously reported for APP. Whether this higher potency
would translate to primary neurons and in vivo is a focus
of future studies. In this paper, this was achieved with a
preliminary determined IC50 in the order of 5μM, in the
absence of toxicity.
Multiple transient transfections of SH-SY5Y cells were
performed with the constructs that either translated
luciferase driven by the 48 base SNCA 5 UTR (SNCA-
5 UTR-pGL3) or the empty pGL3 expression vector (Figures
3 and 4). As shown (Figures 3 and 4), posiphen 50% re-
pressed SNCA 5 UTR-conferred translation of a luciferase
reporter transcript. In this regard, posiphen proved a highly
selective inhibitor of SNCA 5 UTR driven activity since
this chirally pure compound inhibited SNCA 5 UTR-driven
luciferase expression in H2A neural cells (i.e., SNCA 5 UTR-
positive stablytransfected neural cells). Bycontrast, phenser-
ine and the known APP translation blocker, compound
number 9 (included as a comparator), did not suppress8 Parkinson’s Disease
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Figure 4: Selectivity of posiphen to inhibit translation driven by alpha-synuclein 5 UTR sequences: a second set of transient transfection
experimentsinwhichposiphen(10μM)selectivelyinhibitedalpha-synuclein5 UTR-conferredluciferaseexpressioninSH-SY5Yneuralcells
(SNCA 5 UTR-positive transfectants, (N = 6)). Conﬁrming selectivity, posiphen increased luciferase expression in pGL3-transfected SH-
SY5Y cells (∗∗pGL3-SH-SY5Y serves as an experimental control since these cells were transfected with pGL3, which is the same as the H2A
construct but lacks the α-synuclein 5 UTR).
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Figure 5: Metabolic analogs of posiphen and their respective anticholinesterase activities [60]. Posiphen is devoid of anticholinesterase
activity. However, its phase 1 metabolites, N8 demethylated, N1 demethylated, and di-demethylated N1, N8-bisnorposiphen showed ex vivo
AChE and BChE inhibitory activity of clinical relevance [61, 62]. The compound N8-bisnorposiphen demonstrated no AChE activity. This
activity has proven to be dose limiting in human safety studies.Parkinson’s Disease 9
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Figure 6: Percent inhibition of α-synuclein/APP by posiphen compared with its metabolic analogs in primary E18 neurons (from PAC-
Tg(SNCA) mice). Densitometry and quantitation of the relative levels α-synuclein/APP from western blots (β-actin standardized) after
treating primary neurons with posiphen and each of its three metabolic analogs at 100nM concentration for 48 hours.
SNCA 5 UTR conferred translation in H2A cells. Indeed,
phenserineandcompoundnumber9elevatedSNCA5 UTR-
conferred translation.
These data support the mechanism-of-action of posi-
phen as a highly selective blocker of SNCA 5 UTR activity.
However, phenserine—with the identical chemical structure
but in a diﬀerent three-dimensional (chiral) conﬁguration—
that has previously been shown to eﬀectively inhibit transla-
tion driven by the APP 5 UTR clearly has diﬀerent actions
to posiphen at the SNCA 5 UTR. From this, we can
deduce that the element of the SNCA 5 U T Rt a r g e t e db y
posiphen has a stereospeciﬁc component. Additionally, since
phenserine lowers α-syn levels (Figure 2(b)), further SNCA
RNAsequencesarelikelyinvolvedincontrollingthispathway
of α-syn translational regulation.
Extending beyond transformed neuronal cell lines, pri-
maryneuronsfromwild-typemiceandPACSNCAtransgenic
mice (PAC-Tg SNCA) were evaluated for the capacity of
posiphen to repress α-syn expression, as shown in Figure 6
(tested at 100nM drug concentration). Posiphen proved not
only active and well tolerated in SH-SY5Y cells but con-
sistently reduced human α-synuclein expression in primary
neurons (E18) at doses as low as 1uM (75% reduction, not
shown) without toxicity. This margin appeared to be greater
than its capacity to lower APP production (20%) (utilized as
a positive control) in these same cells (data not shown).10 Parkinson’s Disease
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Figure 7: A model for translation repression of alpha-synuclein in which its transcript interacts with an RNA repressor protein. In the
classical translation repression model, Iron-regulatory protein-1 (IRP1) controls iron dependent expression of the ferritin L- and H-chains.
By analogy, phenserine, posiphen and its metabolic analogs would be predicted to increase the repressor as an RNA binding protein to
interact with the SNCA 5 UTR after drug treatment. This should prohibit 40S ribosome access to the 5 UTR of SNCA mRNA to lower
translation.
Following oral administration of posiphen to rodents,
dogs, and human, the compound is subjected to metabolic
processes and generates the same metabolic proﬁle across
thesespecies.Speciﬁcally,viaaphase1metabolism,posiphen
undergoes N-demethylation in both the N1 and N8 posi-
tions to generate the respective primary metabolites, N1-
norposiphen and N8-norposiphen (Figure 5). Each then
undergoes further N-demethylation to generate the com-
monmetabolite,N1,N8-bisnorposiphen.Unlikephenserine,
posiphen is devoid of cholinesterase inhibitory activity and,
therefore, can be advantageously administered at higher
clinical doses (in the order of 5, to 8-fold greater).
As shown in Figure 5, speciﬁc N-demethylated metabo-
lites (in particular the N1-nor and N1,N8-bisnorposiphen)
possess potentially clinically relevant IC50 values to inhibit
acetylcholinesterase (AChE). Such activity is less than
phenserine and would be expected to have a slow onset in
line with the time-dependent metabolism of posiphen to
generate its metabolites. However, with regard to actions
on α-synuclein expression, activity of the metabolites at this
target, where posiphen is potent, could usefully increase
and extend the drug’s in vivo eﬃcacy. To elucidate this and
aid planning for future animal studies, we characterized
the relative capacities of posiphen’s metabolic analogs to
impact α-syn expression (Figure 6).
Figure 6 shows a Western Blot analysis representative of
three experiments that compared the eﬃcacy of posiphen
with that of its three primary metabolites to limit α-
synuclein expression ex vivo using E18 primary cortical
neurons from human SNCA PAC mice. We consistently
measured that N1-norposiphen (possessing AChE activity)
proved most potent to limit α-synuclein expression (by
50%), and, likewise, APP expression was also reduced. As
assessed at 100nM in Figure 6, the other metabolites proved
to be less active at these targets, indicating that relatively
small structural changes (i.e., the loss of a methyl moiety)
have signiﬁcant impact. An assessment of dose-response for
each metabolite is a focus of future studies, particularly
within the achievable clinical range of the agents in human
and in vivo range in animal models (Dr. Maria Maccecchini
and Dr. Robert Nussbaum, personal communications).
4. Conclusions
We previously reported that phenserine, a (-)-physostigmine
analogue and anticholinesterase that reached phase III clin-
ical assessment for AD [53–55], inhibited APP translation
though its 5 UTR [56, 57]. Phenserine was found to be dose
limiting consequent to its AChE inhibitory action, causing
the classical cholinergic action of tremors in animal models
and nausea in humans. Posiphen, the chirally pure (+)
enantiomer of phenserine, by contrast possesses no direct
anticholinesterase activity and, likewise, repressed neuralParkinson’s Disease 11
AD-speciﬁc APP translation via its 5 UTR in mice. It has
recently been developed (QR Pharma, Berwyn, PA) to the
clinicasanAPPsynthesisinhibitorinADtolowerbothbrain
Aβ generation as well as the levels of other toxic proteolytic
products of APP. With a very diﬀerent pharmacological and
pharmacokinetic proﬁle to phenserine, it has recently com-
pleted single-and multiple-dose escalating phase I clinical
assessment in humans, appearing well-tolerated, and a proof
of mechanism study, indicating target engagement.
In this paper, we demonstrated in human immortal neu-
ronal cultures, and then ex vivo in primary cortical neurons
from a human SNCA genomic mouse model, that posiphen
acts as a safe 5 UTR-directed inhibitor of toxic α-synuclein
buildup. A ﬁnal validation of the SNCA 5 UTR target is
to be achieved by unchanged β-synuclein (β-syn) and γ-
synuclein(γ-syn)expressionandisafocusofcurrentstudies.
Importantly, we determined that key primary metabolites of
posiphen, likewise, lower α-syn expression and may hence
addtoposiphen’s actionsonthistargetinanimalandhuman
studies.
Of further interest, we established that phenserine sim-
ilarly eﬀectively reduced α-syn levels but achieves this via a
diﬀerent mechanism, compared to posiphen, potentially by
interacting through other elements in the 5 UTR or even
3 UTR, and thereby highlighting the sensitivity of the target
to small structure-activity changes. These studies addition-
allydemonstratehow α-synucleinandAßpathomechanisms
can converge via interaction of the two amyloidogenic pro-
teins [38–40], although Aß and α-syn rarely co-localize in
amyloid deposits [41], but provide evidence that a drug
targeting one disease may have therapeutic potential in
another.
In this regard, we noted that there is 50% sequence
similarity between the 5  UTRs of the APP and SNCA genes.
We therefore predicted overlap in the spectrum of drugs
that would suppress APP mRNA translation through its
5 UTR with those that suppress α-synuclein, highlighting
in particular phenserine and posiphen (with preliminary
IC50 values in the order of 5μM and less). In future
studies, we aim to characterize the anti-α-synuclein eﬃcacy
of posiphen analogs in addition to metabolic analogs and
other compounds in primary neurons and establish the in
vivo eﬃcacy of the most eﬀective SNCA 5 UTR translation
blockers.
Acknowledgments
The authors thank Prof. Robert Nussbaum and Dr. Yien-
Ming Kuo (UCSF) for their PAC-Tg(SNCA) mice. This re-
search was supported (i) for J. T. Rogers by the Michael J.
Fox Foundation Novel Drug Discoveries Award, National
Institute of Aging R01 AG20181, NINDS R21NS059434,
Alzheimer’s Association Zenith Award 09–131352 and ISOA
(ii) for N. H. Greig by the Intramural Research Program,
National Institute on Aging, National Institutes of Health,
(iii) for I. Cantuti-Caselvetri: the MGH/MIT Morris Udall
Center of Excellence in PD Research (NIH NS38372) and
theAPDAAdvancedCenterforParkinsonResearchatMGH,
and (iv) for C. M. Cahill by NIH HD012437 29 S-1.
References
[1] G.S.StandaertandA.B.Young,“Treatmentofthecentralner-
vous system degenerative disorders,” in Goodman & Gilaman’s
The Pharmacological Basis of Therapeutics, L. L. Brunton, Ed.,
pp. 527–545, McGraw-Hill, New York, NY, USA, 2005.
[2] M. R. DeLong and J. L. Juncos, “Parkinson’s disease and other
movement disorders,” in Harrison’s Neurology in Clinical Med-
icine, S. L. Hauser, Ed., pp. 295–314, McGraw-Hill, New York,
NY, USA, 2006.
[3] L. S. Forno, “Neuropathology of Parkinson’s disease,” Journal
of Neuropathology and Experimental Neurology, vol. 55, no. 3,
pp. 259–272, 1996.
[4] I. Cantuti-Castelvetri and D. G. Standaert, “Neuroprotective
strategies for Parkinson’s disease,” Current Neuropharmacol-
ogy, vol. 2, pp. 153–168, 2004.
[5] K. R. Chaudhuri and Y. Naidu, “Early Parkinson’s disease and
non-motor issues,” Journal of Neurology, vol. 255, no. 5, pp.
33–38, 2008.
[6] K. R. Chaudhuri and P. Odin, “The challenge of non-motor
symptoms in Parkinson’s disease,” Progress in Brain Research,
vol. 184, pp. 325–341, 2010.
[7] K. R. Chaudhuri and A. H. Schapira, “Non-motor symptoms
of Parkinson’s disease: dopaminergic pathophysiology and
treatment,” The Lancet Neurology, vol. 8, no. 5, pp. 464–474,
2009.
[8] K. A. Jellinger, “Synuclein deposition and non-motor symp-
tomsinParkinsondisease,”JournaloftheNeurologicalSciences,
vol. 310, no. 1, pp. 107–111, 2011.
[9] D. O. Claassen, K. A. Josephs, J. E. Ahlskog, M. H. Silber, M.
Tippmann-Peikert, and B. F. Boeve, “REM sleep behavior dis-
order preceding other aspects of synucleinopathies by up to
half a century,” Neurology, vol. 75, no. 6, pp. 494–499, 2010.
[10] R. Postuma and J. F. Gagnon, “Cognition and olfaction in Par-
kinson’s disease,” Brain, vol. 133, no. 12, p. e160, 2010, author
reply e161.
[11] M. A. Hely, W. G. J. Reid, M. A. Adena, G. M. Halliday, and
J. G. L. Morris, “The Sydney Multicenter Study of Parkinson’s
disease: the inevitability of dementia at 20 years,” Movement
Disorders, vol. 23, no. 6, pp. 837–844, 2008.
[12] W. G. J. Reid, M. A. Hely, J. G. L. Morris et al., “A longitudinal
study of Parkinson’s disease: clinical and neuropsychological
correlates of dementia,” Journal of Clinical Neuroscience, vol. 3,
no. 4, pp. 327–333, 1996.
[13] A. Larner, “Cholinesterase inhibitors: beyond Alzheimer’s dis-
ease,” Expert Review of Neurotherapeutics, vol. 10, no. 11, pp.
1699–1705, 2010.
[14] J. T. Olin, D. Aarsland, and X. Meng, “Rivastigmine in the
treatment of dementia associated with Parkinson’s disease:
eﬀects on activities of daily living,” Dementia and Geriatric
Cognitive Disorders, vol. 29, no. 6, pp. 510–515, 2010.
[15] F. A. Schmitt, D. Aarsland, K. S. Brønnick, Xiangyi Meng, S.
Tekin, and J. T. Olin, “Evaluating rivastigmine in mild-
to-moderate Parkinsons disease dementia using ADAS-cog
items,” American Journal of Alzheimer’s Disease and other De-
mentias, vol. 25, no. 5, pp. 407–413, 2010.
[16] F. A. Schmitt, M. R. Farlow, X. Meng, S. Tekin, and J.
T. Olin, “Eﬃcacy of rivastigmine on executive function in
patientswithparkinson’sdiseasedementia,”CNSNeuroscience
& Therapeutics, vol. 16, no. 6, pp. 330–336, 2010.
[17] D. J. Burn, “The treatment of cognitive impairment associated
with parkinson’s disease,” Brain Pathology,v o l .2 0 ,n o .3 ,p p .
672–678, 2010.12 Parkinson’s Disease
[18] J. T. Greenamyre and T. G. Hastings, “Parkinson’s—divergent
causes convergent mechanisms,” Science, vol. 304, no. 5674,
pp. 1120–1122, 2004.
[19] K. Gwinn-Hardy, “Genetics of parkinsonism,” Movement Dis-
orders, vol. 17, no. 4, pp. 645–656, 2002.
[20] D. F. Clayton and J. M. George, “The synucleins: a family of
proteins involved in synaptic function, plasticity, neurodegen-
eration and disease,” Trends in Neurosciences, vol. 21, no. 6, pp.
249–254, 1998.
[21] M. H. Polymeropoulos, C. Lavedan, E. Leroy et al., “Mutation
in the α-synuclein gene identiﬁed in families with Parkinson’s
disease,” Science, vol. 276, no. 5321, pp. 2045–2047, 1997.
[22] M. H. Polymeropoulos, “Autosomal dominant Parkin-
son’s disease and alpha-synuclein,” Annals of Neurology, vol.
44, no. 3, supplement 1, pp. S63–S64, 1998.
[23] H. Braak, K. Del Tredici, U. R¨ u b ,R .A .I .D eV o s ,E .N .H .
Jansen Steur, and E. Braak, “Staging of brain pathology related
tosporadicParkinson’sdisease,”NeurobiologyofAging,vol.24,
no. 2, pp. 197–211, 2003.
[24] C. M. Cahill and J. T. Rogers, “Interleukin (IL) 1β induction
of IL-6 is mediated by a novel phosphatidylinositol 3-kinase-
dependent AKT/IκB kinase α pathway targeting activator
protein-1,” JournalofBiological Chemistry,vol. 283, no. 38, pp.
25900–25912, 2008.
[25] B. Wolozin and N. Golts, “Iron and Parkinson’s disease,”
Neuroscientist, vol. 8, no. 1, pp. 22–32, 2002.
[26] S. Gal, M. Fridkin, T. Amit, H. Zheng, and M. B. H.
Youdim, “M30, a novel multifunctional neuroprotective drug
with potent iron chelating and brain selective monoamine
oxidase-ab inhibitory activity for Parkinson’s disease,” Journal
ofNeuralTransmission,Supplement,no.70,pp.447–456,2006.
[27] C. M. Cahill, D. K. Lahiri, X. Huang, and J. T. Rogers, “Am-
yloid precursor protein and alpha synuclein translation,
implications for iron and inﬂammation in neurodegenerative
diseases,” Biochimica et Biophysica Acta, vol. 1790, no. 7, pp.
615–628, 2009.
[28] J. P. Taylor, I. F. Mata, and M. J. Farrer, “LRRK2: a common
pathway for parkinsonism, pathogenesis and prevention?”
Trends in Molecular Medicine, vol. 12, no. 2, pp. 76–82, 2006.
[29] A. E. Oakley, J. F. Collingwood, J. Dobson et al., “Individual
dopaminergic neurons show raised iron levels in Parkinson
disease,” Neurology, vol. 68, no. 21, pp. 1820–1825, 2007.
[30] O. Weinreb, T. Amit, S. Mandel, and M. B. H. Youdim, “Neu-
roprotective molecular mechanisms of (-)-epigallocatechin-3-
gallate: a reﬂective outcome of its antioxidant, iron chelating
and neuritogenic properties,” Genes & Nutrition,v o l .4 ,n o .4 ,
pp. 283–296, 2009.
[31] I. Cantuti-Castelvetri, J. Klucken, M. Ingelsson et al., “Alpha-
synuclein and chaperones in dementia with Lewy bodies,”
JournalofNeuropathologyandExperimentalNeurology,vol.64,
no. 12, pp. 1058–1066, 2005.
[32] L. Reznichenko, T. Amit, H. Zheng et al., “Reduction of iron-
regulatedamyloidprecursorproteinandβ-amyloidpeptideby
(-)-epigallocatechin-3-gallate in cell cultures: implications for
iron chelation in Alzheimer’s disease,” Journal of Neurochem-
istry, vol. 97, no. 2, pp. 527–536, 2006.
[33] A. L. Friedlich, R. E. Tanzi, and J. T. Rogers, “The 5 -
untranslated region of Parkinson’s disease α-synuclein mes-
sengerRNA contains a predicted iron responsive element [1],”
Molecular Psychiatry, vol. 12, no. 3, pp. 222–223, 2007.
[34] J. T. Rogers, S. Mikkilineni, I. Cantuti-Castelvetri et al., “The
alpha-synuclein 5 untranslated region targeted translation
blockers: anti-alpha synuclein eﬃcacy of cardiac glycosides
and Posiphen,” Journal of Neural Transmission, vol. 118, no.
3, pp. 493–507, 2011.
[35] D. Olivares, X. Huang, L. Branden, N. H. Greig, and J. T.
Rogers, “Physiological and pathological role of alpha-syn-
uclein in parkinson’s disease through iron mediated oxidative
stress; the role of a putative iron-responsive element,” Interna-
tional Journal of Molecular Sciences, vol. 10, no. 3, pp. 1226–
1260, 2009.
[36] K. Ueda, H. Fukushima, E. Masliah et al., “Molecular cloning
of cDNA encoding an unrecognized component of amyloid
in Alzheimer disease,” Proceedings of the National Academy of
Sciences of the United States of America, vol. 90, no. 23, pp.
11282–11286, 1993.
[37] V. M. Y. Lee, B. I. Giasson, and J. Q. Trojanowski, “More than
just two peas in a pod: common amyloidogenic properties of
tau and α-synuclein in neurodegenerative diseases,” Trends in
Neurosciences, vol. 27, no. 3, pp. 129–134, 2004.
[38] P. H. Jensen, P. Hojrup, H. Hager et al., “Binding of Abeta
to alpha- and beta-synucleins: identiﬁcation of segments in
alpha-synuclein/NAC precursor that bind Abeta and NAC,”
Biochemical Journal, vol. 323, no. 2, pp. 539–546, 1997.
[ 3 9 ] K .A .C o n w a y ,J .D .H a r p e r ,a n dP .T .L a n s b u ry ,“ A c c e l e r a t e di n
vitro ﬁbril formation by a mutant α-synuclein linked to early-
onset Parkinson disease,” Nature Medicine, vol. 4, no. 11, pp.
1318–1320, 1998.
[40] Han Hogyu, P. H. Weinreb, and P. T. Lansbury Jr., “The core
Alzheimer’s peptide NAC forms amyloid ﬁbrils which seed
and are seeded by beta-amyloid: is NAC a common trigger or
targetinneurodegenerativedisease?”Chemistry&Biology,vol.
2, no. 3, pp. 163–169, 1995.
[41] J. Q. Trojanowski and V. M. Y. Lee, “Parkinson’s disease and
related neurodegenerative synucleinopathies linked to pro-
gressive accumulations of synuclein aggregates in brain,” Par-
kinsonism&RelatedDisorders,vol.7,no.3,pp.247–251,2001.
[ 4 2 ]J .T .R o g e r s ,J .D .R a n d a l l ,C .M .C a h i l le ta l . ,“ A ni r o n -
responsive element type II in the 5 -untranslated region of the
Alzheimer’s amyloid precursor protein transcript,” Journal of
Biological Chemistry, vol. 277, no. 47, pp. 45518–45528, 2002.
[ 4 3 ]J .A .D u c e ,A .T s a t s a n i s ,M .A .C a t e re ta l . ,“ I r o n - E x p o r tF e r -
roxidase Activity of β-Amyloid Precursor Protein is Inhibited
by Zinc in Alzheimer’s Disease,” Cell, vol. 142, no. 6, pp. 857–
867, 2010.
[44] P. Davies, D. Moualla, and D. R. Brown, “Alpha-synuclein is
a cellular ferrireductase,” PLoS ONE, vol. 6, no. 1, Article ID
e15814, 2011.
[45] P. Davies, X. Wang, C. J. Sarell et al., “The synucleins are a
family of redox-active copper binding proteins,” Biochemistry,
vol. 50, no. 1, pp. 37–47, 2011.
[46] D. K. Lahiri, D. Chen, B. Maloney et al., “The experimental
Alzheimer’s Disease drug posiphen [(+)-phenserine] lowers
amyloid-β peptide levels in cell culture and mice,” Journal of
Pharmacology and Experimental Therapeutics, vol. 320, no. 1,
pp. 386–396, 2007.
[47] I. Nakano and A. Hirano, “Parkinson’s disease: neuron loss in
the nucleus basalis without concomitant Alzheimer’s disease,”
Annals of Neurology, vol. 15, no. 5, pp. 415–418, 1984.
[48] Y. M. Kuo, Z. Li, Y. Jiao et al., “Extensive enteric nervous
system abnormalities in mice transgenic for artiﬁcial chromo-
somes containing Parkinson disease-associated α-synuclein
gene mutations precede central nervous system changes,” Hu-
man Molecular Genetics, vol. 19, no. 9, Article ID ddq038, pp.
1633–1650, 2010.
[49] B. Ray, J. A. Bailey, S. Sarkar, and D. K. Lahiri, “Molecular and
immunocytochemical characterization of primary neuronalParkinson’s Disease 13
cultures from adult rat brain: diﬀerential expression of
neuronal and glial protein markers,” Journal of Neuroscience
Methods, vol. 184, no. 2, pp. 294–302, 2009.
[50] H. H. Cho, C. M. Cahill, C. R. Vanderburg et al., “Selective
translational control of the Alzheimer amyloid precursor
protein transcript by iron regulatory protein-1,” Journal of
Biological Chemistry, vol. 285, no. 41, pp. 31217–31232, 2010.
[51] S. Bandyopadhyay, X. Huang, H. Cho, N. H. Greig, M. B.
Youdim, and J. T. Rogers, “Metal speciﬁcity of an iron-
responsive element in Alzheimer’s APP mRNA 5 untranslated
region, tolerance of SH-SY5Y and H4 neural cells to desfer-
rioxamine, clioquinol, VK-28, and a piperazine chelator,”
Journal of Neural Transmission, Supplement, no. 71, pp. 237–
247, 2006.
[52] M. Maccecchini, “Posiphen’s pharmacokinetics and mecha-
883nism of action in mild cognitive impaired patients,” Alz-
heimer’s & Dementia, vol. 6, no. 4, supplement 1, p. e54, 2010.
[53] B. Winblad, E. Giacobini, L. Fr¨ olich et al., “Phenserine eﬃcacy
in Alzheimer’s disease,” Journal of Alzheimer’s Disease, vol. 22,
no. 4, pp. 1201–1208, 2010.
[ 5 4 ]N .H .G r e i g ,K .S a m b a m u r t i ,Q .S .Y u ,A .B r o s s i ,G .B .
Bruinsma, and D. K. Lahiri, “An overview of phenserine tar-
trate, a novel acetylcholinesterase inhibitor for the treatment
of Alzheimer’s disease,” Current Alzheimer Research, vol. 2, no.
3, pp. 281–290, 2005.
[55] J.Klein,“Phenserine,”ExpertOpiniononInvestigationalDrugs,
vol. 16, no. 7, pp. 1087–1097, 2007.
[56] K. T. Y. Shaw, T. Utsuki, J. Rogers et al., “Phenserine regulates
translation of β-amyloid precursor protein mRNA by a
putative interleukin-1 responsive element, a target for drug
development,” Proceedings of the National Academy of Sciences
of the United States of America, vol. 98, no. 13, pp. 7605–7610,
2001.
[57] A. Venti, T. Giordano, P. Eder et al., “Integrated role of des-
ferrioxamine and phenserine targeted to an iron-responsive
element in the APP-mRNA 5 -untranslated region,” Annals of
the New York Academy of Sciences, vol. 1035, pp. 34–48, 2004.
[58] Y. Xia, T. Saitoh, K. U´ eda et al., “Characterization of the
human α-synuclein gene: genomic structure, transcription
start site, promoter region and polymorphisms,” Journal of
Alzheimer’s Disease, vol. 3, no. 5, pp. 485–494, 2001.
[59] J. B. Goforth, S. A. Anderson, C. P. Nizzi, and R. S. Eisenstein,
“Multiple determinants within iron-responsive elements dic-
tate iron regulatory protein binding and regulatory hierarchy,”
RNA, vol. 16, no. 1, pp. 154–169, 2010.
[60] W. Luo, Q. S. Yu, M. Zhan et al., “Novel anticholinesterases
based on the molecular skeletons of furobenzofuran and
methanobenzodioxepine,” JournalofMedicinalChemistry,vol.
48, no. 4, pp. 986–994, 2005.
[ 6 1 ]Q .S .Y u ,X .F .P e i ,H .W .H o l l o w a y ,N .H .G r e i g ,a n d
A. Brossi, “Total syntheses and anticholinesterase activities
of (3aS)-N(8)-norphysostigmine, (3aS)-N(8)-norphenserine,
their antipodal isomers, and other N(8)-substituted ana-
logues,” Journal of Medicinal Chemistry, vol. 40, no. 18, pp.
2895–2901, 1997.
[ 6 2 ]Q .S .Y u ,N .H .G r e i g ,H .W .H o l l o w a y ,a n dA .B r o s s i ,“ S y n -
theses and anticholinesterase activities of (3aS)-N1,N8-
bisnorphenserine, (3aS)-N1,N8-bisnorphysostigmine, their
antipodalisomers,andotherpotentialmetabolitesofphenser-
ine,” Journal of Medicinal Chemistry, vol. 41, no. 13, pp. 2371–
2379, 1998.